Designation recognizes products that bring improvements to the health
care industry
WAYNE, Pa.--(BUSINESS WIRE)--Nov. 7, 2017--
Teleflex Incorporated (NYSE: TFX) announced its LMA® Gastro™ Airway has
received a 2017 Innovative Technology designation from Vizient,
Inc., the largest member-driven health care performance improvement
company in the country. The designation was based on direct feedback
from hospital experts who interacted with LMA® Gastro™ Airway at the
Vizient Innovative Technology Exchange in Denver on Sept. 14, 2017.
The LMA® Gastro™ Airway from Teleflex is the first laryngeal mask
specifically designed to enable clinicians to proactively manage their
patients’ airways while facilitating direct endoscopic access via the
integrated channel. With the airway in place, clinicians can easily
direct an endoscope and provide a patent airway for patient safety,
which can facilitate monitoring of end tidal CO2.
The use of moderate-to-deep sedation during endoscopy is a common
practice. Respiratory depression from sedative drugs and airway
obstruction requiring intervention are known risks associated with
endoscopic procedures, with studies demonstrating that hypoxemia can
occur in 11-50% of cases.1-3 In the United States there are
more than 6.9 million upper endoscopies performed each year.4
Today, many of these are undertaken without an airway management device
in place.
“Teleflex continues to develop innovative airway management products
through collaboration with clinicians around the world. The introduction
of LMA® Gastro™ provides a controlled airway management solution for
many higher risk patients undergoing routine upper GI procedures,” said
Justin McMurray, President and General Manager, Teleflex Anesthesia and
Emergency Medicine Division. “We are honored to have the LMA® Gastro™
Airway recognized as innovative technology by Vizient and look forward
to a continued relationship with Vizient and clinicians with a focus on
advancing clinical practice.”
“The Vizient Innovative Technology Exchange offers medical technology
suppliers the opportunity to demonstrate their products and gain direct
feedback from the approximately 1,500 clinical experts who attend the
event. Following exploration of the technological capabilities of the
LMA® Gastro™ Airway at the Exchange, attendees recommended it receive an
Innovative Technology designation. Congratulations to Teleflex on
receiving this status,” said Debbie Archer, director of procurement and
Vizient Innovative Technology Program leader.
Vizient represents a diverse membership base that includes academic
medical centers, pediatric facilities, community hospitals, integrated
health delivery networks and non-acute health care providers, with more
than $100 billion in annual purchasing volume. Through its Innovative
Technology Program, Vizient works with member-led councils and task
forces to review potentially innovative products. If it is determined
that a product is innovative, Vizient may award a contract outside of
the competitive bid cycle.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people's lives. We apply
purpose-driven innovation - a relentless pursuit of identifying unmet
clinical needs - to benefit patients and healthcare providers. Our
portfolio is diverse, with solutions in the fields of vascular and
interventional access, surgical, anesthesia, cardiac care, urology,
emergency medicine and respiratory care. Teleflex employees worldwide
are united in the understanding that what we do every day makes a
difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®,
Rüsch® and Weck® - trusted brands united by a common sense of purpose.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
Teleflex, the Teleflex logo, Cuff Pilot, Deknatel, Hudson RCI, LMA, LMA
Gastro, Pilling, Rüsch, and Weck are trademarks or registered trademarks
of Teleflex Incorporated or its affiliates, in the U.S. and/or other
countries.
© 2017 Teleflex Incorporated. All rights reserved. MC-003914
References
-
Cote GA, Hovis RM, Ansstas MA, et al. Incidence of sedation-related
complications with Propofol use during advanced endoscopic procedures. Clin
Gastroenterol Hepatol. 2010;8(2):137-142.
-
Qadeer MA, Rocio Lopez A, Dumot JA, Vargo JJ. Risk factors for
hypoxemia during ambulatory gastrointestinal endoscopy in ASA I-II
patients. Dig Dis Sci. 2009;54(5):1035-1040.
-
de Paulo GA, Martins FP, Macedo EP, Goncalves ME, Mourao CA, Ferrari
AP. Sedation in gastrointestinal endoscopy: a prospective study
comparing nonanesthesiologist-administered Propofol and monitored
anesthesia care. Endosc Int Open. 2015;3(1):E7-E13.
-
Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease
in the United States: 2012 update. Gastroenterology.
2012;143(5):1179-1187 e1171-1173.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171107005145/en/
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President, Investor Relations
610-948-2836